Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
64,994,031
-
Share change
-
+1,713,259
-
Total reported value
-
$3,143,069,159
-
Put/Call ratio
-
56%
-
Price per share
-
$48.36
-
Number of holders
-
273
-
Value change
-
+$116,416,679
-
Number of buys
-
153
-
Number of sells
-
124
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q1 2025
As of 31 Mar 2025 Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) had 273 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 64,994,031 shares of stock of the company.
Largest 10 holders included BlackRock, Inc., FARALLON CAPITAL MANAGEMENT LLC, RTW INVESTMENTS, LP, VANGUARD GROUP INC, Deep Track Capital, LP, STATE STREET CORP, BVF INC/IL, JOHNSON & JOHNSON, GEODE CAPITAL MANAGEMENT, LLC, and PRICE T ROWE ASSOCIATES INC /MD/.
This table shows 273 institutional shareholders of the security as of 31 Mar 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.